PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Pathophysiology • Diagnosis • Manifestations of cystic fibrosis PART 06: Pipeline analysis PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by drug class • CFTR modulators • Mucolytics • PERT • Anti-infectives • Bronchodilators PART 09: Market segmentation by molecule type • Small molecules • Biologics PART 10: Geographical segmentation • Global cystic fibrosis therapeutics market by geography • Cystic fibrosis therapeutics market in Americas • Cystic fibrosis therapeutics market in EMEA • Cystic fibrosis therapeutics market in APAC PART 11: Key leading countries • The US • The UK • France • Canada • Italy PART 12: Market drivers • Special regulatory designations for drugs • Increased uptake of CFTR modulators • Improvement in diagnostic technologies PART 13: Impact of drivers PART 14: Market challenges • Discontinuation of drugs from development • Difficulty in developing drugs due to rarity of disease PART 15: Impact of drivers and challenges PART 16: Market trends • Co-pay and assistance programs by vendors • Strategic collaborations • Advances in technology for drug development and delivery PART 17: Vendor landscape • Competitive scenario • Other prominent vendors PART 18: Key vendor analysis • Vertex Pharmaceuticals • F. Hoffmann-La Roche • AbbVie • Gilead Sciences • Novartis PART 19: Appendix • List of abbreviations PART 20: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria for global cystic fibrosis therapeutics market 2015 Exhibit 03: Key customer segments of cystic fibrosis therapeutics market Exhibit 04: Snapshot of cystic fibrosis Exhibit 05: Defects caused by CFTR mutation Exhibit 06: Diagnosis of cystic fibrosis Exhibit 07: Pipeline portfolio: Global cystic fibrosis therapeutics market Exhibit 08: Global cystic fibrosis therapeutics market: Market overview 2015 Exhibit 09: Global cystic fibrosis therapeutics market snapshot: Developed and emerging markets 2015 Exhibit 10: Global cystic fibrosis therapeutics market 2015-2020 ($ billions) Exhibit 11: Opportunity analysis: Global cystic fibrosis therapeutics market Exhibit 12: Impact of factors affecting the market 2015 and 2020 Exhibit 13: Five forces analysis Exhibit 14: Global cystic fibrosis therapeutics by drug class 2015 Exhibit 15: Global cystic fibrosis therapeutics market by molecule type 2015 Exhibit 16: Global cystic fibrosis therapeutics market by geography 2015-2020 Exhibit 17: Percentage share of global cystic fibrosis therapeutics market by geography 2015 and 2020 Exhibit 18: Global cystic fibrosis therapeutics market by geography 2015-2020 ($ billions) Exhibit 19: Global share of cystic fibrosis therapeutics market by geography 2015 Exhibit 20: Global cystic fibrosis therapeutics market by region: Market growth lifecycle analysis 2015 Exhibit 21: Global cystic fibrosis therapeutics market: Country analysis based on revenue and growth rate Exhibit 22: Opportunity analysis: Cystic fibrosis therapeutics market in Americas Exhibit 23: Cystic fibrosis therapeutics market in Americas 2015-2020 ($ billions) Exhibit 24: Opportunity analysis: Cystic fibrosis therapeutics market in EMEA Exhibit 25: Cystic fibrosis therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 26: Opportunity analysis: Cystic fibrosis therapeutics market in APAC Exhibit 27: Cystic fibrosis therapeutics market in APAC 2015-2020 ($ millions) Exhibit 28: Key leading countries for cystic fibrosis therapeutics market Exhibit 29: Impact of drivers and challenges on global cystic fibrosis therapeutics market Exhibit 30: Few drugs with breakthrough therapy designation for cystic fibrosis Exhibit 31: Drugs with orphan drug designation for cystic fibrosis Exhibit 32: Impact of drivers Exhibit 33: Few cystic fibrosis therapeutics discontinued from development Exhibit 34: Impact of drivers and challenges Exhibit 35: Global cystic fibrosis therapeutics market: Impact assessment of key trends Exhibit 36: Few cystic fibrosis therapeutics with patient assistance programs Exhibit 37: Key vendors ranking 2015 Exhibit 38: Geographical presence of key vendors 2015 Exhibit 39: Competitive scenario of market vendors 2015-2020 Exhibit 40: Vertex Pharmaceuticals: Profile Exhibit 41: Vertex Pharmaceuticals: Strength analysis Exhibit 42: Vertex Pharmaceuticals: Growth strategy matrix Exhibit 43: Vertex Pharmaceuticals: Opportunity assessment Exhibit 44: Vertex Pharmaceuticals: Revenue of ORKAMBI and Kalydeco 2015 ($ millions) Exhibit 45: F. Hoffmann-La Roche: Profile Exhibit 46: F. Hoffmann-La Roche: Strength analysis Exhibit 47: F. Hoffmann-La Roche: Growth strategy matrix Exhibit 48: F. Hoffmann-La Roche: Opportunity assessment Exhibit 49: F. Hoffmann-La Roche: YoY growth and revenue generated from sales of Pulmozyme 2013-2015 ($ millions) Exhibit 50: AbbVie: Profile Exhibit 51: AbbVie: Strength analysis Exhibit 52: AbbVie: Growth strategy matrix Exhibit 53: AbbVie: Opportunity assessment Exhibit 54: AbbVie: YoY growth and revenue of Creon 2013-2015 ($ millions) Exhibit 55: Gilead Sciences: Profile Exhibit 56: Gilead Sciences: Strength analysis Exhibit 57: Gilead Sciences: Growth strategy matrix Exhibit 58: Gilead Sciences: Opportunity assessment Exhibit 59: Novartis: Profile Exhibit 60: Novartis: Strength analysis Exhibit 61: Novartis: Growth strategy matrix Exhibit 62: Novartis: Opportunity assessment

Vertex Pharmaceuticals, F. Hoffmann-La Roche, AbbVie, Gilead Sciences, Novartis, Advanced Inhalation Therapies (AIT), Alaxia SAS, Alcresta Therapeutics, AlgiPharma, Allergan, Anthera, AstraZeneca, Bayer, Celtaxsys, Chiesi Farmaceutici, Corbus Pharmaceuticals, Cyclacel Pharmaceuticals, Digestive Care, Galapagos, Grifols, Insmed Incorporated, Kamada, Nivalis Therapeutics, Novoteris, Parion Sciences, Pharmaxis, ProQR Therapeutics, Protalix Biotherapeutics, Proteostasis Therapeutics, PTC Therapeutics, Pulmatrix, Savara, SolAeroMed, Vectura.